Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immuno-oncology technologies and next-generation biologic therapeutics. With a focus on addressing hard-to-treat cancers and other severe medical conditions, Xenetic leverages its proprietary platforms to develop transformative therapies that improve patient outcomes.
Core Technologies
The company's flagship technology, the DNase-based oncology platform, is designed to target neutrophil extracellular traps (NETs), which are implicated in cancer progression, metastasis, and resistance to existing therapies. By reducing NETs burden in the tumor microenvironment, Xenetic's DNase platform enhances the efficacy of immunotherapies, adoptive cell therapies, and chemotherapies. This technology is being developed as an adjunctive treatment for pancreatic carcinoma, colorectal cancer, and other locally advanced or metastatic solid tumors.
Another key innovation is the PolyXen™ platform, which improves the pharmacological properties of biologic drugs, including extended half-life and reduced immunogenicity. This platform is being utilized in collaborations with global pharmaceutical companies to develop next-generation biologics, such as polysialylated blood coagulation factors.
Pipeline and Partnerships
Xenetic's pipeline includes investigational therapies targeting significant unmet needs in oncology. The company is advancing its systemic DNase program into clinical trials, focusing on its potential as an adjunctive therapy in combination with chemotherapy and immune checkpoint inhibitors. Preclinical studies have demonstrated encouraging results, including enhanced tumor suppression, improved T-cell activation, and prolonged survival in animal models.
Collaborations play a pivotal role in Xenetic's strategy. The company has established partnerships with institutions such as the University of Virginia and PeriNess Ltd., leveraging their expertise to accelerate preclinical and clinical development. Additionally, Xenetic's sublicense agreement with Takeda Pharmaceuticals for the PolyXen platform generates royalty revenues, supporting its broader research and development efforts.
Market Position and Competitive Edge
Operating within the highly competitive oncology sector, Xenetic differentiates itself through its focus on NET-targeting therapies and its ability to enhance existing treatment paradigms. By addressing the immunosuppressive tumor microenvironment and improving the efficacy of established therapies, the DNase platform holds the potential to transform treatment outcomes for patients with aggressive and resistant cancers.
The company's emphasis on collaboration, coupled with its proprietary technologies, positions it as a key innovator in the field of immune-oncology. Its strategic focus on hard-to-treat cancers underscores its commitment to addressing significant unmet medical needs.
Conclusion
With a robust pipeline, cutting-edge technologies, and strategic partnerships, Xenetic Biosciences Inc. is at the forefront of developing novel therapies that aim to redefine cancer treatment. By targeting critical mechanisms like NETs and leveraging its expertise in biologics, the company continues to make strides toward delivering impactful solutions for patients and healthcare providers.
Xenetic Biosciences (NASDAQ: XBIO) has announced a definitive agreement for a private placement with a healthcare-focused institutional investor. The transaction involves the sale of 4,629,630 shares of common stock at $2.70 per share, amounting to $12.5 million in gross proceeds. The investor will also receive warrants to purchase an equal number of shares at $3.30 per share. The placement is expected to close around July 28, 2021. The funds will be utilized for general working capital purposes, aiding the advancement of their XCART technology for cancer treatment.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q1 2021, showing a net loss of approximately $1.3 million. The company is advancing its XCART platform, a personalized CAR T therapy targeting B-cell lymphomas, with an exploratory patient biopsy trial initiated in Eastern Europe. Additionally, royalty payments of $0.2 million were received from Takeda under an exclusive license agreement. Research and development expenses increased by 75.1% to $0.6 million due to XCART investments, while working capital decreased by $1.2 million to approximately $10.2 million.
Xenetic Biosciences (NASDAQ: XBIO) announced that CEO Jeffrey Eisenberg will present at the Q2 Virtual Investor Summit on May 18, 2021, at 3:30 PM ET. The event will include a live video webcast accessible on the company's IR Calendar page and will be archived for 90 days. Xenetic focuses on advancing its XCART™ personalized CAR T platform, targeting patient-specific neoantigens for B-cell lymphomas. The company also leverages its PolyXen® drug delivery platform and holds an exclusive agreement with Takeda Pharmaceuticals.
Xenetic Biosciences (NASDAQ: XBIO) announced approval for an exploratory study of its XCART platform to target Non-Hodgkin lymphoma (NHL) patients in Eastern Europe. The study aims to refine the process of neoantigen identification and CAR T candidate generation. Conducted at the Vitebsk Regional Clinical Oncological Center in Belarus, it will enroll adult B-Cell NHL patients, enabling further development of autologous CAR T-Cells. Collaborations with Scripps Research and PJSC Pharmsynthez are instrumental in advancing XCART technology, paving the way for future IND-enabling studies in the U.S.
Xenetic Biosciences (NASDAQ: XBIO) reported its 2020 financial results, highlighting advancements in its XCART™ platform aimed at targeting tumor-specific antigens, with a focus on B-cell lymphomas, representing a market opportunity exceeding $5 billion annually. The company reduced its R&D expenses to $1.7 million from $4.9 million in 2019. The net loss for 2020 was approximately $10.9 million, with cash reserves of $11.5 million. Recent partnerships aim to enhance XCART development, and the company anticipates key milestones including an exploratory study in Eastern Europe and regulatory meetings.
Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company, announced on March 3, 2021 that its CEO, Jeffrey Eisenberg, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing its XCART™ technology, designed to target specific neoantigens in tumors. A video presentation will be available on-demand starting March 9, 2021, at 7:00 AM ET. Xenetic is known for developing personalized CAR T therapies for B-cell lymphomas and utilizing its PolyXen® platform to enhance drug delivery.
Xenetic Biosciences (NASDAQ: XBIO) announced that its partner, PJSC Pharmsynthez, has filed a registration dossier for Epolong in Russia to treat anemia in chronic kidney disease patients. This follows positive Phase 3 clinical trial data demonstrating Epolong's efficacy. The collaboration utilizes Xenetic's PolyXen technology to enhance Epolong's pharmacological properties. If approved, Epolong would be the first product using PolyXen, with production expected to begin in Q1 2022. Pharmsynthez aims to complete registration by the end of 2021.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its CEO, Jeffrey Eisenberg, will present at NobleCon17 on January 19, 2021, at 9:45 AM ET. The virtual conference is free to attend and will feature a high-definition video webcast of the presentation.
The company focuses on advancing XCART, a personalized CAR T platform targeting tumor-specific neoantigens for treating B-cell lymphomas. Additionally, Xenetic utilizes its proprietary PolyXen drug delivery platform to enhance biologic drugs, in partnership with other biotech firms.
Xenetic Biosciences (NASDAQ:XBIO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. CEO Jeffrey Eisenberg will present during a fireside chat, with a video webcast available for on-demand viewing starting January 11 at 6:00 AM ET. The company focuses on advancing its XCART™ personalized CAR T platform targeting tumor-specific neoantigens, and it leverages its PolyXen® drug delivery platform for biotech partnerships.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced the closing of a registered direct offering on December 14, 2020, selling 2,448,980 shares at $2.45 each, generating approximately $6.0 million in gross proceeds. The funds will be allocated to general corporate purposes and the advancement of the proprietary XCART technology for treating B-cell Non-Hodgkin lymphomas. The offering was conducted under a shelf registration statement with H.C. Wainwright & Co. serving as the exclusive placement agent.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What does Xenetic Biosciences specialize in?
What is the DNase-based oncology platform?
What are Xenetic's key collaborations?
How does the PolyXen™ platform work?
What types of cancers is Xenetic targeting?
What differentiates Xenetic Biosciences from competitors?
Does Xenetic generate revenue?
What stage is Xenetic's DNase program in?
